Daniel M. Skovronsky, M.D., Ph.D., is a distinguished leader in the field of medical research and development, currently serving as the Executive Vice President, Chief Scientific Officer, and President of Lilly Research Laboratories and Lilly Immunology at Eli Lilly and Company. Dr. Skovronsky's academic journey is marked by his dual degrees in medicine and neuroscience from the University of Pennsylvania, where he also completed his residency in neuropathology. His early career was distinguished by his role as a neuropathologist at the University of Pennsylvania, where he focused on neurodegenerative diseases, a field in which he has made significant contributions through his research. Before joining Eli Lilly, Dr. Skovronsky co-founded Avid Radiopharmaceuticals, a company dedicated to developing innovative imaging agents for the diagnosis of Alzheimer's disease and other neurological disorders. Under his leadership, Avid Radiopharmaceuticals developed florbetapir F 18, an imaging agent that was later approved by the FDA and acquired by Eli Lilly in 2010. This acquisition marked the beginning of Dr. Skovronsky's tenure at Eli Lilly, where he has since risen to his current leadership roles. At Eli Lilly, he oversees the company's research and development efforts, driving the advancement of new therapies across various therapeutic areas, including immunology. In his current position, Dr. Skovronsky is instrumental in shaping the strategic direction of Lilly's research initiatives, with a focus on translating scientific discoveries into meaningful treatments for patients. His leadership has been pivotal in the development of several key drugs, including those targeting Alzheimer's disease and diabetes. His commitment to innovation and patient-centric research continues to drive Lilly's mission to improve global health outcomes. Dr. Skovronsky's contributions to the field have been recognized with numerous awards and honors, reflecting his significant impact on both the scientific community and the lives of patients worldwide.